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Foreword & Type 2 diabetes mellitus is a chronically progressive disease that is characterised by inherited and acquired insulin resistance and an increasing insulin secretion disorder. In order to reduce the morbidity and mortality rates among type 2 diabetics, which are increased signifi cantly by macro-and microangiopathic complications, besides the antihyperglycaemic therapy discussed here it is also essential to administer the optimum treatment for arterial hypertension (see also DDG guideline " Managing hypertension in patients with diabetes mellitus " ), diabetic dyslipidaemia (see also DDG guideline on " Lipid metabolism disorders " , in preparation), and hypercoagulopathy that are often associated with type 2 diabetes. The eff ectiveness of a multifactorial intervention in reducing macro-and microvascular complications Gaede lute risk lowered by 20 % in 13.3 years) ( Gaede et al., 2008, EC Ib ) has been demonstrated convincingly by the results of the Steno-2 study. The favourable eff ect of an optimised antihyperglycaemic treatment in terms of reducing microvascular complications has been shown equally convincingly in the UKPDS (relative risk reduction ~ 40 % ) (UKPDS 33, 1998, EC Ib) and the ADVANCE study ( The ADVANCE Collaborative , EC Ib ). Moreover, the 10-year follow-up data from the UKPDS which was published recently attests to the long-term benefi ts of intensifi ed antihyperglycaemic therapy in reducing macrovascular end points such as myocardial infarction ( Holman et al., 2008, EC Ib ) . A recently published meta-analysis of the eff ects of antihyperglycaemic therapy on macrovascular results in patients with type 2 diabetes reported a relative risk reduction of 19 % ( Stettler et al., 2006, EC Ia ) . Because of the chronically progressive nature of the disease, the antihyperglycaemic treatment must be selected according to the pathophysiological phase of the disease at the time the treatment is begun (see also fl owchart of " Antihyperglycaemic treatment for type 2 diabetes: [2.0]). At the same time, non-pharmacological therapies (structured patient education, nutrition therapy (see also DDG guideline " Nutrition and diabetes mellitus " , as well as exercise therapy) are extremely important in all phases of the disease. In the context of the data from the UKPDS, the UKPDS 10-year follow-up, and ADVANCE, and in accordance with the European Diabetes Policy Group (Desktop Guide to Type 2 Diabetes mellitus) as well as the global IDF guidelines, the target range for HbA1c recommended in this guideline is < 6.5 % . In the light of the recently published results of the ACCORD and ADVANCE studies, however, it is also imperative to avoid adverse side eff ects such as severe hypoglycaemia and significant weight gain ( The Action to Control Cardiovascular Risk in Diabetes Study , EC Ib; The ADVANCE Collaborative , EC Ib ). The appendix to this guideline (starting on p.64) includes the position statement of the DDG with respect to both of these studies. This statement has also been posted on the DDG homepage: http://www.deutsche-diabetesgesellschaft.de/redaktion/news/ACCORD_ADVANCE_DDG_ Stellungnahme_2008_07_09.pdf The conclusions to be drawn from the results of the two studies have been incorporated in the fl owchart (see section 2.0) and in the associated legend (see section 2.1). Endpoint data are available for the following substances in the pharmacological antihyperglycaemic treatment of subjects with type 2 diabetes: metformin, glibenclamide, insulin, pioglitazone, and rosiglitazone. Cardiovascular endpoint data of this kind is not yet available for the other substances listed in this guideline, and there is as yet little long-term information for the newer compounds for obvious reasons. Antihyperglycaemic treatment of diabetes mellitus type 2 is monitored in the medium to long term range by measuring HbA1c, and as a rule this should be done every three months. Moreover, the treatment is monitored in the short term by measuring blood glucose. This should be carried out in consultation with the treating physician taking into consideration the objectives of treatment, the current metabolic situation, current treatment, and other individual, social and organisational factors. In theory, blood glucose self-measurements should be taken regularly by the patient if therapeutic implications for the short, medium and long terms are derived from the results. The frequency with which the patient should monitor his / her own blood glucose levels is dictated by the individual treatment plan, which in turn is prepared taking into account the treatment objective, quality and stability of metabolic control, and the treatment strategy and other factors. A positive relationship between self-testing and the course of the disease has been shown for example in the ROSSO study ( Martin et al., 2006, EC Iib ) . Accordingly, self-testing is also an integral component in the treatment of type 2 diabetes. The objective of this guideline for antihyperglycaemic treatment of diabetes mellitus type 2 is to provide treating physicians with assistance when they are selecting the appropriate treatment for each of their patients, and thus reduce the burden not only on the patients but also on their circle of friends and family. In the light of the marked heterogeneity of type 2 diabetes, this guideline is only able to establish a framework and indicate therapeutic options, within which the physician is expected to implement the individualised treatment strategy jointly with the patient. Accordingly, no guideline will claim absolute authority regarding the treatment of all patients, and particularly not of individual problems; however, documented justifi cations should be provided for deviations from the guidelines. 60 % of the maximum hypoglycaemic eff ect of metformin was observed with a dosage of 1 500 mg / day. Increasing the metformin dosage from 2 000 to 3 000 mg / day only reduced fasting blood glucose levels by a further 5 % , while the incidence of gastrointestinal side eff ects rose sharply.
Antihyperglycaemic effi cacy
Two meta-analyses ( Hermann et al., 1994 , EC Ia ; Campbell et Howlett, 1995, EC Ia ) of all the prospective and randomised studies that had been conducted between 1957 and 1994 revealed that the eff ects of metformin and sulphonylureas appear to be identical on HbA1c (decrease of approx. 1.2 % ), fasting blood glucose (decrease of 30 -40 mg / dl) and postprandial blood sugar values (decrease of approx. 30 mg / dl). Even more pronounced eff ects on fasting blood glucose and HbA1c were observed in studies conducted in the USA, though this may be attributable to the higher starting values in the US studies.
Endpoint data with metformin
The results of the UKPDS study showed unequivocally that improved diabetes control led to a signifi cant reduction in microvascular complications (UKPDS 33, 1998, EC Ib), and that the risk reduction was identical in all therapy groups (sulphonylureas, metformin, insulin). On the other hand, macrovascular complications such as stroke, coronary events and diabetes-related death were only reduced signifi cantly by metformin (UKPDS 34, 1998, EC Ib), though it should be noted that this eff ect was not observed until after the sixth year of treatment. Since the reduction in HbA1c was comparable for sulphonylureas, metformin and insulin, the macrovascular vasoprotective eff ect of metformin reported in the UKPDS can only be explained by its activity on other -probably non-traditional cardiovascular -risk factors -or by mechanisms resulting in plaque stabilisation, but not by its activity in lowering blood sugar levels.
Eff ect on other components of the metabolic syndrome 1.1.1.1.5.1 Eff ect on lipid parameters
It has been demonstrated in several studies ( Johnston et al., 1990 EC Ila ) that a signifi cant increase in the HDL cholesterol levels and a fall in VLDL triglycerides are observed during treatment with metformin (see Table 1 ). In a randomised doubleblind comparative study (n = 1 199) between metformin and pioglitazone, very diff erent eff ects on lipid metabolism were observed while the improvement in diabetes control was identical (Schernthaner et al., 2004, EC Ib) . The fall in triglycerides ( − 19 % vs. − 10 % ; p < 0.001) and the increase in HDL cholesterol ( + 14 % vs. + 7 % , p < 0.001) were much more pronounced with pioglitazone than with metformin, but the eff ect on LDL cholesterol was less benefi cial with pioglitazone ( + 8 % vs. − 3 % ; p < 0.001). Concerning the pertinent total cholesterol / HDL cholesterol ratio, identical results were observed for both monotherapies ( − 8 % vs. − 8 % ; NS). In the combination therapies with various oral antidiabetics too, very diff erent eff ects on the individual lipid fractions were found despite exactly the same HbA1c-lowering eff ect, though it is important to note that even combination antidiabetic therapies are rarely capable of regulating complex diabetic dyslipaemia ( Schernthaner, 2005 , EC IV ).
Antithrombotic eff ects
In 2 studies ( Vague et al., 1987 ; EC IIa ; Nagi & Judkin, 1993, EC Ila ), metformin therapy was observed to cause a signifi cant fall in PAI-1, which is associated with reduced triglyceride levels. Metformin was also observed to have a direct eff ect on PAI-1 synthesis. An additional antithrombotic eff ect of metformin was observed in its favourable activity against increased thrombocyte aggregation ( Gin et al., 1988 , EC Ila ). Moreover, when metformin was administered to an animal model, a signifi cant reduction of AGE formation was reported, by 25 % with a low dose, and by 72 % with a high dose, respectively ( Tanaka et al., 1999 ) . In the DPP study (Diabetes Prevention Program), patients with glucose intolerance showed a reduction in CRP following a year-long course of treatment with metformin; levels were , though it should be noted that the eff ect in the group that modifi ed its lifestyle was much more pronounced ( − 23 % and − 33 % , respectively). In summary, it seems that the vasoprotective eff ect of metformin that was demonstrated in the UKPDS is attributable to the fact that the substance has a beneficial eff ect on several of the known risk factors for atherosclerosis: 1) hyperglycaemia 2) dyslipaemia 3) coagulation disorders 4) endothelial dysfunction 5) chronic vascular infl ammation.
Recent studies suggest that the risk of mortality for combination therapy using metformin may be determined by the sulphonylurea that is used. In an Italian observation study of 2 002 patients with diabetes mellitus type 2 ( Monami et al., 2006, EC III ) , 696 subjects received a combination therapy of insulin secretagogues with biguanides. Mortality after 3 years was signifi cantly higher for the combination therapy with glibenclamide (8.7 % ) than for repaglinide (3.1 % ; p = 0.002), gliclazid (2.1 % ; p = 0.001) or glimepiride (0.4 % ; p < 0.0001). Even after adjusting for many infl uencing factors, the risk of mortality with the metformin-glibenclamide combination was signifi cantly greater, more than doubled (OR 2.09).
In view of the above, the authors do not believe that switching all diabetic patients who are treated with these combinations is indicated, however, they do recommend the application of stricter indication guidelines, particularly for new patients and for those with coronary artery disease. Particularly favourable results have been described for the combination of insulin and metformin (Yki-J ä rvinen et al., 1999, EC Ib). Besides marked lowering of HbA1c, by as much as 2.5 % , positive eff ects on body weight as well as an insulin-saving eff ect were described (Yki-J ä rvinen et al., 1999, EC Ib).
Side eff ects
Gastrointestinal side eff ects, namely nausea, fullness, bloating, diarrhoea and a metallic taste in the palate are side eff ects that are not uncommon when treatment with metformin is initiated, and in about 5 % of patients these persist, causing treatment to be discontinued. The most common side eff ects are loss of appetite and fullness, diarrhoea is relatively rare. The most dangerous side eff ect is lactic acidosis, which is extremely uncommon. Metformin was originally approved for treating diabetes in the USA in 1995. In Germany before the UKPDS (1998), metformin could only be used in combination therapy with sulphonylureas, and it should be noted that precisely the combination with glibenclamide that was used frequently then is now associated with possibly unfavourable mortality data. Exactly 50 years after its introduction, metformin is undergoing a renaissance of a kind that is highly unusual and even unprecedented for a drug ( Schernthaner, 2007 , EC IV ). In the ADA-EASD Guidelines, metformin was recommended as a primary pharmacotherapy in combination with lifestyle modifi cation for all patients regardless of their body weight (Nathan et al., 2006, EC IV) . In an Australian retrospective observational study, metformin was observed to produce at least equally good results for patients of normal weight as for overweight patients in terms of diabetes control ( Ong et al., 2006 , EC III ). Today, metformin is used in combination with all other available antidiabetic medications (insulin, sulphonylureas, glinides, glitazones, gliptins, GLP-1 agonists), wherein both its effi cacy and particularly its contribution to weight control appear attractive. In the ADOPT study ( Kahn et al., 2006 ) , patients receiving monotherapy treatment with metformin were compared with those taking rosiglitazone only, and a weight diff erence of 6.9 kg was found after just 3 years of treatment. In the QUARTET study as well, the diff erence in weight between metformin and pioglitazone was 3.9 kg after just one year (Schernthaner et al., 2004, EC Ib 
Alpha-glucosidase inhibitors (AGI)
Alpha-glucosidase inhibitors (AGI) are enzyme inhibitors that prevent di-and oligosaccharides from being hydrolysed to monosaccharides in the intestines. Since only monosaccharides are easily absorbed into the blood from the intestines, a fraction of the oligosaccharides consumed with food remains in the intestines. This reduces the postprandial rise in blood sugar levels and the quantity of sugar absorbed. Clinical data is available in the literature for three AGIs, acarbose, miglitol and voglibose. Currently, only acarbose and miglitol are approved for use in Germany. Therefore, voglibose is not mentioned in this guideline. . Postprandial reduction of D-dimer and prothrombin fragments, and therewith also a possible reduction in the degree of activation of haemostasis was observed in type 2 diabetics receiving acarbose ( Ceriello et al., 1996, EC Ib ) (recommendation grade C). In a population with impaired fasting glucose (IFG), acarbose was not shown to reduce endothelial dysfunction in a substance-specifi c manner, but rather as a result of reduced hyperglycaemia (Wascher et al., 2005, EC Ib) (recommendation grade C). The clinical relevance of these changes for the patient has not yet been established in any valid studies, so they should not form the primary basis for any decision regarding treatment.
Side eff ects
Gastrointestinal complaints such as bloating, fl atulence, diarrhoea and abdominal pain are the most common side eff ects of AGIs, and their respective frequency is in the order the complaints are listed. They are caused by fermentation of unused carbohydrates in the intestine. The complaints occur most often in the fi rst few weeks after treatment starts. The scale and frequency of these side eff ects are determined by the individual ' s glucosidase activity, and are clearly dependent on the dosage of AGIs (van de Laar et al., 2005, evidence class Ia) (recommendation grade A). Since the additional antihyperglycaemic eff ect of high doses of acarbose is weak, high doses should be avoided (see also section 1.1.1.2.2). Initially, up to 50 % of patients may experience gastrointestinal side eff ects with AGIs, compared with 30 % who receive a placebo. It is therefore important to increase the dosage gradually. In this way, the associated intestinal symptoms at start may be reduced to below 30 % ( May, 1995, EC IIa ) (recommendation grade B) and the discontinuation rate for new patients may be reduced to less than 3 % ( Fischer et al., 1998; EC I b ) (recommendation grade A). Over a prolonged period, however, some of those patients who experience strong side eff ects may become less observant of their regimen (Holman et al., 1997, evidence class Ib), (recommendation grade A). Severe side eff ects seldomly occur with AGIs. Individual case reports of the development of hepatitis and ileus with AGIs have been published. If AGIs are used in combination with insulinotropic medications or insulin, hypoglycaemia can only be treated orally or with glucose and not with oligosaccharides.
Contraindications
AGIs are contraindicated for patients younger than 18 and those who are pregnant. Contraindications also exist for patients with chronic infl ammatory intestinal diseases, and also for hernias, spastic colon, ileus and subileus. AGIs should not be administered in the case of severe renal insuffi ciency (creatinine clearance < 25 ml / min).
Summary: Advantages and disadvantages of AGIs
AGIs are drugs that lower blood glucose levels by preventing oligosaccharides (di-and oligosaccharides) from being broken down to glucose. As a result, a fraction of the carbohydrates that are consumed in food remains in the intestine and is not made available for resorption. Because of their pharmacologically different mechanism of action, AGIs can be used in combination with other antihypergycaemic compounds and have an additive antiglycaemic eff ect. An eff ect on surrogate parameters has been demonstrated, but no endpoint studies are available. Since they only lower HbA1c and blood glucose slightly, AGIs alone are not usually eff ective enough to achieve the treatment objective of a near-normoglycaemic blood glucose levels. Severe side eff ects occur rarely, but gastrointestinal side eff ects are frequent, and they tend to discourage patients from adhering to the treatment regimen. AGIs are drugs that should be used as complementary treatments and after careful consideration of the additional therapeutic eff ect and benefi t expected.
Advantages
Disadvantages -can be used in combination with all therapy principles (diet, oral antidiabetics, insulin) with added eff ect -does not aff ect weight -no risk of hypoglycaemia -life-threatening side eff ects are extremely rare -no primary endpoint study -gastrointestinal side eff ects common -poor therapy observance due to frequent side eff ects -HbA1c lowered only slightly This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 
Triple combination therapy (rosiglitazone)
For patients whose blood sugar is not suffi ciently controlled despite oral double combination therapy with metformin and sulphonylureas ( Dailey et al., 2004 , EC Ib ) and for whom insulin therapy would entail professional limitations (e. g. carriage of passengers). Achievement of the HbA1c therapeutic objective should be realistic with the triple combination therapy. (Technical information on Avandia ® March 2008, Technical information on Actos ® , August 2007).
Combination therapy with insulin (pioglitazone)
For patients whose blood sugar is insuffi ciently controlled with insulin and for whom metformin is not suitable due to contraindications or intolerance (Technical information on Actos ® , August 2007).
Dosage

Dosage of rosiglitazone
Rosiglitazone therapy is usually started at 4 mg / daily. This dose can be increased to 8 mg / daily after 8 weeks if necessary. Rosiglitazone can be administered in one or two doses per day, whereby the antihyperglycaemic effi cacy is individually greater with two administrations per day than with one, without resulting in a signifi cant diff erence. In combination with a sulphonylurea, care should be taken when increasing the dosage to 8 mg / d. It should be preceded by an appropriate medical examination to assess the risk of fl uid retention occurring. Rosiglitazone can be taken with or without food. For patients of advanced age, the dosage does not need to be adjusted, though particular attention must be paid to cardiac insuffi ciency and fl uid retention. For patients with mild to moderate renal insuffi ciency (creatinine clearance > 30 ml / min), the dosage does not need to be adjusted, in the case of severe renal insuffi ciency (creatinine clearance < 30 ml / min), rosiglitazone should only be used with extreme caution because very few study results are available (Technical information on Avandia ® March 2008).
Dosage of pioglitazone
Pioglitazone therapy can be started at a dosage of 15 or 30 mg and increased incrementally up to 45 mg, once a day. Pioglitazone can be taken with or without food. In combination with insulin, the prior dosage of insulin can be retained when treatment with pioglitazone begins. If the patient has a history of hypoglycaemia, the insulin dosage should be reduced. For patients of advanced age, the dosage does not need to be adjusted. For patients with impaired renal function (creatinine clearance > 4 ml / min), the dosage does not need to be adjusted. No information is available with regard to dialysis patients, so these patients must not receive pioglitazone (Technical information on Actos ® , August 2007). Table 1A shows a summary of studies that examined the antihyperglycaemic effi cacy of a glitazone therapy compared to other OADs. The results of these studies show that the antihyperglycaemic effi cacy of glitazone therapy is comparable to other OADs. There is a comparison of the sustained therapeutic eff ect of initial monotherapies for diabetes mellitus type 2 with rosiglitazone, metformin and glyburide ( Kahn et al. 2006 , ADOPT study, EC Ib). After fi ve years, therapy failure -defi ned as fasting blood sugar > 180 mg / dl -was observed in 15 % of patients treated with rosiglitazone, 21 % of patients treated with metformin, and 34 % patients treated with glyburide. The diff erences were signifi cant.
Antihyperglycaemic effi cacy
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Eff ect on cardiovascular endpoints
In the ProActive study, after 36 months pioglitazone led to a nonsignifi cant relative risk reduction of 10 % for the primary endpoint (overall mortality, non-fatal myocardial infarction, stroke, major lower limb amputation, acute coronary syndrome, cardiac intervention (CABG, PCI), revascularisation of arteries of the lower limb) for patients who had a history of a macrovascular event. A significant relative risk reduction of 16 % was observed for the secondary (cardiovascular) endpoint (myocardial infarction, stroke, death). The " number-needed-to-treat " in order to prevent a macrovascular event is 144 / year ( Dormandy et al., 2005, EC Ib ). In the group that was treated with pioglitazone, the fraction of patients who had to begin an insulin therapy fell by 46.9 % compared to placebo. 1.6 % more patients in the pioglitazone group than in the placebo group were hospitalised for cardiac insuffi ciency. 21.6 % of the patients in the pioglitazone group and 13.0 % of the patients in the placebo group experienced edema. A meta-analysis by Eurich showed a reduction in overall mortality for glitazone patients with known cardiac insuffi ciency, but at the same time an increased risk of admission to hospital for decompensation due to cardiac insuffi ciency ( Eurich et al., 2007 , EC Ia ).
Nissen & Wolski (2007, EC Ia) published a meta-analysis of 42 studies with rosiglitazone as the study medication, which detected a signifi cant increase in the risk of myocardial infarction (Odds ratio 1.43) when rosiglitazone medication was used compared with control groups (placebo and comparison substances). In this analysis, the risk of mortality from cardiovascular causes was also greater for rosiglitazone therapy (Odds ratio 1.64) but just missed the signifi cance level (p = 0.06). The associated editorial listed the following weaknesses of this analysis: relatively small number of cardiovascular events; analysis only of summary study data, not of individual patient data, and consequently the time before the event and dose event relationships were not recorded; control groups with placebo and comparison medication were not distinguished; no standard method for diagnosing and securing endpoints. 
Advantages Disadvantages
-pathophysiologically orientated therapy (lowering of visceral lipid accumulation, reduction of gluconeogenesis) -weight gain This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Combination therapy with non-β -cytotropic medications
The next section describes the combination therapies of biguanides with α -glucosidase inhibitors and biguanides with PPAR-γ ligands (rosiglitazone and pioglitazone). The third, theoretically possible combination therapy ( α -glucosidase inhibitors with PPAR-γ ligands) is not approved; moreover, no data relating to this possible combination has yet been published.
Biguanides and α -glucosidase inhibitors 1.1.1.4.1.1 Indication
For patients with type 2 diabetes who have not reached their HbA1c target value with either of the two substances in mono-therapy (Rosenstock et al., 1998 , EC Ib; Chiasson et al., 1994, EC Ib ) (recommendation grade A).
Antihyperglycaemic effi cacy
The results of the acarbose arm of the UKPDS study showed that patients who received acarbose in addition to various prior therapies (including metformin) experienced an average HbA1c reduction of 0.5 % (in the group of patients who took acarbose for a period of 3 years (39 % of the acarbose arm); in the full cohort of the acarbose arm, HbA1c was lowered by 0.2 % ) ( Holman et al., 1999, EC Ib ) (recommendation grade B). Table 2 lists the previously published studies on the eff ect of supplementary therapy with rosiglitazone or pioglitazone for type 2 diabetics who have been unable to achieve adequate control with prior metformin therapy.
β -cytotropic oral antidiabetics: potassium channel blockers
Sulphonylureas, repaglinide and nateglinide stimulate insulin secretion by blocking the ATP-sensitive potassium channels in the plasma membrane of β -cells. ( Panten et al., 1996, EC IV ). This β -cytotropic eff ect occurs in hyper-, normo-and hypoglycaemia depending on dosage. Direct eff ects of the sulphonylureas glibenclamide and glimepiride on non-β cells have also been described, though their role in the clinical eff ect thereof is still unclear and disputed. In chemical terms, repaglinide and nateglinide are not sulphonylureas, but their molecular structures are closely related to sulphonylureas (Panten et al., 1996, EC IV). Repaglinide and nateglinide diff er from the sulphonylureas that are available in Germany mainly in their short duration of action and rapid elimination. Taken directly before main meals, they are designed to serve the pathophysiologically defi ned objective, particularly of lowering rises in prandial blood glucose levels and reducing the incidence of postprandial hypoglycaemia.
Sulphonylureas 1.1.2.1.1 Indication
For patients with diabetes mellitus type 2 in conjunction with non-pharmacological measures (education, nutrition therapy, increase in physical activity) for whom intolerance / 
Dosage
According to the manufacturer ' s instructions, therapy with any of the sulphonylureas available in Germany should be started gradually at the following daily doses: 1.75 -3.5 mg glibenclamide, 12.5 mg glibornuride, 40 mg gliclazid, 1 mg glimepiride, 15 mg gliquidone, 0.5 -1 g tolbutamide. The manufacturer also provides instructions for increasing the dosage incrementally if metabolism is not controlled satisfactorily (up to maximum daily doses of 10.5 mg glibenclamide, 75 mg glibornuride, 240 mg gliclazide, 6 mg glimepiride, 120 mg gliquidone, or 2 g tolbutamide) and recommendations to take the entire daily dose at breakfast for low and medium dosages, and to take half each of high doses in the morning and evening. In the case of glimepiride, it is emphasised that the preparation only needs to be taken once a day (in the morning). But glibenclamide should also be taken only once a day (up to 7 mg in the morning), because there are no clinical studies that confi rm any advantage in taking the dosage of glibenclamide several times in the day, and because taking another 3. . However, the retrospective design of all of these studies makes it impossible to rule out the possibility that the groups treated with sulphonylurea and particularly sulphonylurea and metformin in combination included an unusually high proportion of patients with more advanced diabetes and greater cardiovascular risk.
Contraindications
Sulphonylureas are contraindicated in ▶ Type 1 diabetes ▶ Complete secondary failure of a therapy that includes sulphonylureas or analogues thereof, particularly in the case of compensation for metabolic acidosis, precoma or coma ▶ Pancreatectomy ▶ Impaired renal function (treatment with gliquidone possible under strict supervision) ▶ Severe liver function disorders ▶ Hypersensitivity to sulphonylureas and (because of crossallergies) sulphonamide antimicrobial agents, sulphonamide diuretics and probenecid ▶ Relatively major surgical procedures, accidents and infections that may possibly entail post aggression syndrome ▶ Planned or current pregnancy and while nursing Tolbutamide and gliquidone are also contraindicated in acute porphyria. Gliclazide is also contraindicated if the patient is using miconazol.
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Repaglinide is deactivated by CYP2C8, so that administering a second CYP2C8 substrate (e. g., gemfi brozil) at the same time can prolong (elimination half-life period prolonged to 3.7 h) and reinforce the eff ect. In rare cases, repaglinide can cause gastrointestinal disorders (e. g., nausea, feeling of having overeaten) and allergic reactions. Also in rare cases, nateglinide can cause elevated liver enzyme values and trigger allergic reactions.
Repaglinide is contraindicated ▶ In combination with gemfi brozil or any other active agent that is metabolised by CYP2C8 ▶ Repaglinide and nateglinide are contraindicated in ▶ Type 1 diabetes ▶ Complete secondary failure of a therapy that includes sulphonylureas or analogues thereof, particularly in the case of compensation for metabolic acidosis, precoma or coma ▶ Pancreatectomy ▶ Severe liver disorders ▶ Hypersensitivity to repaglinide or nateglinide ▶ Relatively major surgical procedures, accidents and infections that may possibly entail post aggression syndrome ▶ Planned or current pregnancy and during nursing
Advantages and disadvantages of sulphonylurea analogues
Advantages Disadvantages
-pronounced eff ect on postprandial blood glucose -pronounced eff ect on postprandial blood glucoseRisk of hypoglycaemia -weight gain -lack of endpoint data -no extensive experience in longterm application -safety in combination with metformin or glitazone not established This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 
.3.1 β -cytotropic substances and metformin
In patients with type 2 diabetes whose metabolism was not controlled satisfactorily with sulphonylurea in monotherapy, metabolic control was improved by a supplementary therapy with metformin (UKPDS 34, 1998, EC Ib). However, the combination with glibenclamide or chlorpropamide led to a rise in diabetesrelated deaths (compared to a sulphonylurea monotherapy; UKPDS 34, 1998, EC Ib; Nathan, 1998 , EC IV). This unfavourable result was explained by the authors by the subsequent change to the study medication. A number of retrospective studies, some with very large patient cohorts, gave no indication that the combination was associated with greater cardiovascular risk ( Gulliford . Given their retrospective design, it is not possible to confi rm for any of these studies that they did not include an unusually high proportion of higher risk patients in the group treated with this combination. Even so, the benefi t-risk ratio of the combination therapy of a sulphonylurea with metformin is still not established with regard to cardiovascular endpoints. Therapy with a metformin-repaglinide or metformin-nateglinide combination led to a greater HbA1c reduction than a metformin monotherapy (Moses et al., 1999, EC Ib; Horton et al., 2000, EC Ib ). Increased risk of mortality cannot be ruled out even for therapy with the metformin plus sulphonylurea analogue combination, because no long-term studies have been published on this subject and the β -cytotropic action of sulphonylurea analogues is based on the same mechanism of action as that of sulphonylureas themselves. Long-term studies regarding the safety of metformin-repaglinide combination therapy are also needed because repaglinide does not distinguish between the various sulphonylurea receptor subtypes (see 1.1.2.2.4).
β -cytotropic substances and α -glucosidase inhibitors
In patients with type 2 diabetes whose metabolism has not been controlled satisfactorily with sulphonylurea in monotherapy, additional therapy with an α -glucosidase inhibitor may be considered. In an additional therapy with acarbose or miglitol, HbA1c has been lowered by a further 0. . As yet, there is no endpoint data available for the combination therapy of a β -cytotropic substance with an α -glucosidase inhibitor.
β -cytotropic substances and PPAR-γ ligands
For patients with type 2 diabetes not tolerating metformin or with contraindications and who are unable to reach their HbA1c goal with a sulphonylurea or glinide monotherapy, a supplementary therapy with a PPAR-γ ligand may be considered (see Table 3 ). Dailey et al. compared a triple therapy consisting of metformin / glibenclamide / rosiglitazone with a combination therapy of metformin / glibenclamide. After 24 weeks, a signifi cantly greater reduction in fasting blood sugar and the HbA1c value was observed for the triple therapy than for the double therapy ( Dailey et al., 2004, EC Ib ). Rosenstock et al. compared the eff ect of 10 U / day insulinglargine with 4 mg / day rosiglitazone in patients whose HbA1c was between 7.5 and 11 % on a combination therapy of metformin and sulphonylureas. After 24 weeks, there was no signifi cant diff erence between the eff ects on the HbA1c value in the two groups. Fasting blood sugar was lowered signifi cantly more with the insulin-glargine combination (Rosenstock et al., 2006 , EC Ib).
DPP-4 inhibitors
DPP-4 inhibitors are a new class of oral antidiabetics, which inhibit the enzyme dipeptidyl-peptidase IV (DPP-4). DPP-4 is a key enzyme that determines the rate of degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP) as well as other regulatory peptides ( Mentlein R 1999, EC IV ). Inhibiting DPP-4 has the eff ect of increasing the endogenous concentrations of these peptides and thus also strengthening their eff ect, particularly that of endogenous GLP-1. GLP-1 stimulates insulin secretion based on the presence of glucose and only under conditions of hyperglycaemia, and inhibits glucagon secretion by the pancreatic alpha cell. These actions are primarily responsible for the antihyperglycaemic properties of DPP-4 inhibitors, and they disappear when blood sugar values fall below the normal range. Accordingly, DPP-4 inhibitors do not present any intrinsic risk of hypoglycaemia. They are also body weight neztral. In animal models, DPP-4 inhibitors manifest favourable infl uences on islet function and morphology but whether these infl uences are also refl ected in humans has yet to be determined ( Gallwitz B 2007, EC IV ). The DPP-4 inhibitors described in the literature, sitagliptin, vildagliptin and others, are chemically diff erent and do not form a unifi ed substance class. Consequently, the individual substances This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
cannot be compared directly with each other in terms of pharmacodynamics and pharmacokinetics ( Barnett A 2006, EC IV ). At the moment, only sitagliptin and vildagliptin have been approved for market release in Germany. Therefore, only these two substances will be described in the following section, particularly with reference to indications, dosage, and contraindications.
Indication
Sitagliptin and vildagliptin have been approved for oral combination therapy. For patients with type 2 diabetes whose metabolism is unsatisfactorily controlled despite a change in lifestyle and oral medication with metformin, additional therapy with these DPP-4 inhibitors may be considered, particularly if hypoglycaemia prevention (e. g. professional activity factors, concomitant diseases, patient safety) or control of bodyweight is also a primary therapeutic objective. There are also fi xed combination preparations for sitagliptin and vildagliptin with met-formin. A therapy with sitagliptin or vildagliptin may also be an option for patients with type 2 diabetes who cannot reach their metabolic therapy objectives on monotherapy with a PPAR-γ agonist, particularly if they are intolerant of metformin and / or it is contraindicated for them. Approval also exists for the combination of DPP-4 inhibitors with a sulphonylurea, which is also an option if a combination of the sulphonylurea with metformin is not possible for the reasons given above or PPAR-γ agonists or alpha-glucosidase inhibitors are not suitable. Both DPP-4 inhibitors can also be administered in addition to an existing combination of metformin with sulphonylurea if the therapeutic objectives are not reached with this double combination alone. The benefi t-risk ratio of these forms of combination therapy with DPP-4 inhibitors has not yet been defi ned because of insuffi cient experience with their long-term use. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. tle information is available yet on this issue. If they are used, the dose should then be reduced based on pharmacokinetic data, i. e., 50 mg / day sitagliptin for a GFR < 50 ml / min and only 25 mg / die for a GFR < 30 ml / min. Patients with mildly or moderately impaired liver function (Child-Pugh Score 9) also do not need to adjust the dosage of sitagliptin, but vildagliptin should not be given to any patients with impaired liver function or transaminase levels more than three times above the normal range.
Antihyperglycaemic effi cacy
The antihyperglycaemic effi cacy of DPP-4 inhibitors was investigated in monotherapy and in various combinations with other oral antidiabetics. In a systematic meta-analysis of the clinical studies that were available at the time, administration of DPP Table 4 shows the results of the meta-analysis with reference to the HbA1c outcomes, . In a study of the combination therapy of vildagliptin with insulin for patients who received vildagliptin additionally because their metabolism was inadequately controlled with insulin alone, the incidence (p < 0.001) and severity (p < 0.05) of hypoglycaemia in the vildagliptin group was significantly lower than in the placebo group (Fonseca et al., EC Ib, Recommendation grade A).
Side eff ects
Overall, the DPP-4 inhibitors are well tolerated, low rates of side eff ects were reported in the clinical studies. In a comparison with placebo, gastrointestinal side eff ects (nausea, vomiting, diarrhoea, abdominal pain) were not observed any more frequently than for placebo. In a summary evaluation of all studies that could be evaluated, the therapy with DPP-4 inhibitors presented a slightly greater incidence of nasopharyngitis (6. When vildagliptin was taken in single doses greater than 50 mg twice a day and more, very rare cases (incidence no more than 0.3 % ) of impaired liver function were observed, the symptoms of which were mostly subclinical. In these cases, liver values returned to normal when administration was discontinued, and there were no after-eff ects. The elevated transaminase levels were not progressive and were not associated with cholestasis or jaundice. Transaminase levels should be determined before beginning treatment with vildagliptin (as it should before beginning treatment with glitazones or statins as well) and then every three months for the fi rst year of the treatment.
Contraindications
Sitagliptin and vildagliptin are contraindicated for patients with type 1 diabetes, patients younger than 18 years, and in pregnancy. Moreover, these DPP-4 inhibitors should not be administered to patients with moderate or severe renal insuffi ciency (creatinine clearance < 50 ml / min).
Summary: Advantages and disadvantages of DPP-4
inhibitors DPP-4 inhibitors are drugs that function as " incretin enhancers " to inhibit the degeneration of endogenous incretin hormones (GLP-1, GIP). In hyperglycaemic conditions, insulin secretion is stimulated depending on the presence of glucose, and at the same time the excessive glucagon secretion that takes place in type 2 diabetes is inhibited. Because their mechanism of action is pharmacologically diff erent from that of other compounds, DPP-4 inhibitors can be used in combination with such medications, and in this case they have an additive antiglycaemic eff ect. The combination with metformin is especially favourable, particularly with regard to weight control and the risk of hypoglycaemia, which is comparable with placebo. There are currently no endpoint studies available for DPP-4 inhibitors. Severe side eff ects are rare, but there is currently no information regarding long-term eff ects. DPP-4 inhibitors are agents that can be used as an addition to therapy with metformin, thiazolidinediones or sulphonylureas, if the therapy objective could be reached with these, and if it is important to avoid weight gain or hypoglycaemia.
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Indication
Incretin mimetics are peptides that are capable of activating the receptor for Glucagon-Like-Peptide-1. The only incretin mimetic that has been approved so far is exenatide. It is indicated in combination with metformin and / or sulphonylurea preparations for treating diabetes mellitus type 2 patients whose blood glucose has not been controlled satisfactorily with the maximum tolerable dose of these oral therapies. In general, the eff ect of lowering blood glucose in monotherapy has also been documented No approval has been granted for these additional indications. Exenatide has been investigated in randomised studies lasting up to 52 weeks with respect to glucose control (HbA1c), body weight, blood pressure, as well as safety and tolerability. There have been no studies regarding its long-term safety or hard clinical endpoints. Exenatide is a therapy option for patients who are unable to control their metabolism adequately with the maximum tolerable dosage of metformin and / or sulphonylureas and who would otherwise have to begin a regimen of insulin therapy. At the moment, the benefi t-risk ratio compared with insulin therapy can only be evaluated on the basis of surrogate parameters and so remains undetermined.
Dosages
Exenatide is available as a pre-fi lled pen device with a delivery volume of 5 μ g or 10 μ g per dose. According to the manufactur-er ' s information, and in keeping with relevant study results (Finman et al., 2004, EC Ib) treatment should initially be administered subcutaneously at a level of 5 μ g per dose, twice daily, once before breakfast and once before the evening meal. After 4 weeks, if the patient tolerates the dosage well and the required eff ect has not been achieved, the 5 μ g dose may be increased to 10 μ g per dose. This higher dose can be expected to lower HbA1c more eff ectively, but also to have a more pronounced benefi t in terms of reducing body weight ( 
Antihyperglycaemic effi cacy
Injecting exenatide twice a day lowers HbA1c values by 0.8 to 1.1 % ( 
Eff ect on body weight
Weight loss is usually experienced after several weeks of treatment with exenatide ( . This is also true for patients receiving exenatide as monotherapy. If sulphonylureas are used, the improved blood glucose control exenatide provides does cause more frequent episodes of hypoglycaemia. When exenatide is combined with sulphonylureas, the advantages (improved effi cacy) must be weighed up carefully against the special risks (risk of hypoglycaemia).
Side eff ects
When treatment with exenatide is started, up to 50 % of patients may experience adverse gastrointestinal eff ects such as nausea, wretching, vomiting and diarrhoea caused by the medication. These side eff ects are usually assessed as mild to moderate. In 3.0 to 6.6 % of cases, nausea is evaluated as severe (studies listed in Table 6 ), and in 1.8 to 14.0 % of cases, treatment was discontinued because of adverse gastrointestinal eff ects of the medication. 9.6 % of patients (7.1 to 15.7 % ) discontinued the treatment in the studies because of adverse eff ects of the medication, 5.7 % because of gastrointestinal side eff ects. Gradually increasing the dosage (initially 5 μ g twice a day, 10 μ g per dose after 4 weeks) helps to prevent gastrointestinal side eff ects (Finman et al., 2004, EC Ib). Gastrointestinal side eff ects are often experienced shortly after the start of treatment or after the dose is increased and they often diminish as the treatment time progresses. As a foreign protein, exenatide provokes antibody production in about 45 % of the patients treated (studies listed in Table 6 ). These antibodies are described as low-affi nity and low-titre. Antibody formation is not associated with side eff ects. It is not clear whether the clinical treatment with exenatide is obstructed in some cases by higher-titre antibodies. A few cases of acute pancreatitis have been observed with exenatide. In most cases, typical risk constellations (gallstones, alcohol, etc.) for pancreatitis were implicated. The frequency of the cases of acute pancreatitis reported in association with exenatide does not exceed the expected frequency of such events in a population of patients suff ering from type 2 diabetes. A causal relationship between exenatide therapy and the onset of an acute pancreatitis episode cannot be asserted defi nitively.
Advantages and disadvantages of exenatide.
Advantages Disadvantages
-glucose control without risk of hypoglycaemia (provided it is not combined with sulphonylureas) -weight loss -lowered blood pressure -in preclinical studies, positive eff ects on betacell function and mass -gastrointestinal side eff ects -insuffi cient experience regarding long-term use -antibody formation with suspected loss of effi cacy -possible interaction with other drugs due to delayed gastric emptying -Risk of hypoglycaemia when combined with sulphonylureas
Contraindications
Contraindication exists in the case of hypersensitivity to the active agent or any one of the other components. Exenatide should not be used to treat patients with type 1 diabetes or diabetic ketoacidosis. Exenatide should not be given to type 2 diabetics for whom insulin therapy is necessary as a result of beta-cell failure. Care must be taken in the case of patients with gastrointestinal diseases, particularly if these are accompanied by delayed motility of the gastrointestinal tract (e. g., gastroparesis). Administration of exenatide together with insulin, fast-acting sulphonylurea analogues and α -glucosidase inibitors has not been studied adequately and cannot be recommended. Clinical experience is very limited for patients aged over 75. For patients with moderately impaired renal function (creatinine clearance 30 -50 ml / min), the dose escalation from 5 μ g to 10 μ g should be undertaken with extreme caution. Therapy with exenatide cannot be recommended for patients with terminal renal insufficiency or severe renal function disorders (creatinine clearance < 30 ml / min). No prior experience is available for adolescents under the age of 18 years.
Insulin therapy
Insulin is administered to correct insulin defi ciency, promote the uptake of glucose by peripheral tissues after meals, and reduce glucose toxicity. Insulin also suppresses hepatic glucose production, which is the fundamental cause of basal hyperglycaemia in type 2 diabetics. Insulin also corrects other metabolic disorders, such as excessive lypolysis, and has a benefi cial eff ect on blood lipids ( Emanuele et al., 1998, EC Ib ) (recommendation grade A) and the clotting system ( Jain et al., 1993, EC Ib ) (recommendation grade A). Finally, the UKPD study (UKPDS 33, 1998, EC Ib) (recommendation grade A) demonstrated that insulin is instrumental in lowering microvascular endpoints, whereas a reduction in macrovascular endpoints did not reach a level of signifi cance. Insulin has the most powerful eff ect of all pharmacological products that are designed to lower blood sugar.
Indication
Insulin therapy for type 2 diabetics is indicated whenever the individual therapeutic objective is not achieved with dietary measures and oral antidiabetics, or if contraindications exist for oral antidiabetics (recommendation grade A). There are no evidence-based endpoint studies indicating that a given form of insulin therapy is superior to any other. The respective form of insulin therapy must therefore be selected individually for each patient. Short-term insulin therapy may become necessary in This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
the case of surgical procedures or more severe illnesses. Finally, insulin therapy is indicated for pregnant type 2 diabetics and female patients with gestational diabetes if metabolism cannot be controlled optimally with dietary measures alone (recommendation grade A).
Blood glucose self monitoring
Every insulin therapy should be accompanied by a self-check of blood glucose ( European Diabetes Policy Group, 1999 , EC IV ) [recommendation grade A)). This enables hypoglycaemia to be detected early, diabetic control to be better monitored, and the insulin dose to be adjusted to the respective blood glucose level and the planned carbohydrate uptake in insulin regimens. The time and frequency of such blood glucose self-checks must be defi ned individually and depends largely on the type of insulin therapy in question. Insulin therapy and blood glucose selfchecks must be supported by intensive education, which enables the patient to respond appropriately to the blood glucose values obtained. The blood sugar measurements should be taken often enough to achieve the individual ' s treatment goal. 
Application
The large number of treatment regimens serves as the basis for a wide variety of insulin therapy options for treating type 2 diabetes. In general, a distinction is made between conventional insulin therapy (CT), intensifi ed conventional insulin therapy (ICT), and combination therapy (insulin plus oral antidiabetics).
The choice regarding which of these therapies to implement must be guided by consideration for the patient ' s individual needs, quality of life and degree of metabolic control. Even today, there are no evidence-based studies of the advantages and disadvantages of the various therapy regimens in terms of clinically relevant endpoints. In the UKPD study, both conventional and intensifi ed insulin therapy were used, but no evaluation of the various regimens was carried out (UKPDS 33, 1998 Group, 1993 , EC Ib ) its results indicated an advantage of intensifi ed insulin therapy with several insulin injections per day over the conventional therapy with 1 -2 insulin injections per day in terms of reducing the risk of microvascular complications. In a randomised, controlled multicentre study ( Abraira et al., 1998, EC Ib ) that was conducted with 153 obese (BMI 30.7 kg / m2) type 2 diabetics and lasted an average of 27 months, HbA1c was lowered more eff ectively with intensifi ed insulin therapy than with conventional or combination therapies. However, no conclusions regarding clinically relevant endpoints could be drawn within the framework of this study. Yki-J ä rvinen and associates ( Yki-J ä rvinen et al., 1992, EC Ib ) compared combination therapy with conventional and intensifi ed therapy with 153 type 2 diabetics in a 3 -month, randomised, controlled study, and were unable to fi nd any advantages in any of the various insulin regimens with regard to optimising glucose metabolism, although the HbA1c was signifi cantly lower in all groups that received insulin than in the control group that only received oral antidiabetics. Weight gain with insulin therapy was lowest in the group with combination therapy and highest in the group with intensifi ed insulin therapy, which is why combination therapy was preferred.
Insulin administration
Nowadays, insulin is usually administered with insulin pens. These pens are simple to use, provide an exact dose, and cause considerably fewer administration errors than disposable insulin syringes. Disposable insulin syringes are also suitable for administering insulin. However, the user must be particularly careful to note whether they are calibrated for U-100 or U-40 insulin. Patients must be educated accordingly. Injection sites should be easy to reach and readily visible. The most frequently used site is the stomach, the upper thigh is recommended for NPH insulin, but this site can also be used for other insulins if necessary. If possible, no other sites should be used for autoinjection. A fold should be made in the skin before injecting (recommendation grade C).
Conventional therapy
In conventional therapy, insulin is usually injected twice a day, in the morning and evening, before meals on both occasions. In less common cases, insulin only needs to be taken once a day (usually in the morning). Normally, a mixed insulin is used, consisting of 25 to 30 % regular insulin and 70 -75 % NPH insulin. In the case of mixed insulin, it is advisable to leave a period of about 15 -30 min between injecting and eating, depending on the preprandial blood sugar level (the higher the blood sugar value, the longer the period between injecting and eating). Insulins with a diff erent mix proportions may also be appropriate depending on the behaviour of the blood glucose. For this purpose mixed insulins with varied mix proportions are available (15 / 85, 25 / 75, 30 / 70, 50 / 50). Combination insulin analogues with a fi xed mix proportion of a short-acting insulin analogue and a delayed insulin in protamine crystal suspension are also available for conventional therapy. The average daily dose of insulin is between 0.5 and 1.0 U / kg bodyweight, and the insulin units are allocated roughly in proportions of 2 / 3 in the morning and 1 / 3 in the evening. In many cases, however, this allocation must be adjusted to individual circumstances, and substantially higher insulin doses are often necessary because of strong insulin resistance. Insulin therapy is generally begun with a small number of units, e. g., 8 -10 units in the morning and 4 -6 units in the evening. The dose is then increased incrementally until the glucose target values are reached. In order to pursue a conventional therapy successfully, it is necessary to follow an ordered daily routine with fi xed times for injections and eating. The quantity of insulin and eating and portioning of carbohydrates must be adapted to the individual. After a mix insulin has been injected, the pharmodynamics of This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
this insulin make it often necessary that about 4 -5 h after injection another carbohydrate-containing meal must be eaten in order to avoid hypoglycaemia. Many patients must also eat snacks between meals to avoid hypoglycaemia, which is unfavourable in view of the weight problems that often accompany the condition. Moreover, hypoglycaemia may also be triggered by unanticipated physical exertion. The conventional therapy thus demands a certain amount of rigidity in the way many patients lead their lives. Blood glucose self-checks and any necessary adjustments to the insulin dose in accordance with an insulin dosage adjustment schedule should also be carried out regularly.
Intensifi ed conventional insulin therapy
The questions of when, how and for whom an intensifi ed insulin therapy (ICT) may be suitable must be determined for each patient individually. In intensifi ed insulin therapy, the patient has greater fl exibility in terms of his or her daily routine and nutrition, which in turn may result in improved quality of life. In the Kumamoto study, the intensifi ed insulin therapy brought about an improvement in the HbA1c value, which in turn resulted in reduced microvascular endpoints (Ohkubo et al., 1995, EC Ib) . Intensifi ed insulin therapy is indicated whenever adequate metabolic control cannot be achieved with a conventional insulin therapy or a combination therapy (oral antidiabetics (OAD), OAD + basal insulin) (recommendation grade A). In order to initiate intensifi ed insulin therapy, it is recommended to administer short-acting insulin before meals, adjusted to the current blood glucose level and the planned size of the meal, at fi rst without subsequent administration of an intermediate acting insulin ( Kalfhaus et al., 2000, EC III ). The practice of taking short-acting insulin on its own before meals only works in the long term for a small number of patients. For example, 41 % of patients in a study including 77 type 2 diabetics ( Kalfhaus et al., 2000, EC III ) needed a dose of NPH insulin in the evening in order to control their fasting blood glucose adequately. Otherwise, for type 2 diabetics with normal bodyweight, an ICT is administered in the same way as for type 1 diabetics, though individual factors for carbohydrate consumption and correction must be defi ned. Obese, insulin-resistant type 2 diabetics often need very high doses of short-acting insulin, and calculating carbohydrates is of little help in most cases (recommendation grade B). Prandial insulin therapy or ICT can be administered to type 2 diabetics with normal insulin or insulin analogues (Insulin lispro (Humalog ® ) or Insulin aspart (Novorapid ® )) or insulin glulisin (Apidra ® ). The potential advantage of insulin analogues is that they can be injected immediately before meals, patients most often do not have to eat snacks between meals to avoid hypoglycaemia, postprandial blood glucose spikes can be controlled more eff ectively, and according to some studies the tendency to hypoglycaemia is less pronounced than with normal insulin. For example, one 6-month randomised crossover multicentre study with 722 type 2 diabetics ( Anderson et al., 1997, EC Iia ) showed that postprandial blood glucose spikes were lower and hypoglycaemia occurred less frequently with Insulin lispro than with human insulin. Insulin aspart and insulin glulisin were also observed to regulate postprandial blood glucose values better than normal insulin ( At present, there are no endpoint studies relating to long-acting insulin analogues. Two recently published studies compared various insulin therapy strategies for patients with type 2 diabetes. The results of the " Treating to Target in Type 2 Diabetes (4-T) " study (basal insulin vs. prandial insulin vs. mixed insulin in the context of an established OAD therapy) showed that HbA1c was lowered signifi cantly more with prandial insulin and mixed insulin therapies than with the basal insulin therapy. However, this eff ect was associated with an elevated risk of hypoglycaemia and pronounced weight gain ( Holman et al., 2007, EC Ib ) .
Combination therapy with insulin and oral antidiabetics
In the Apollo study, an insulin / OAD combination therapy with one-time administration of insulin glargine was compared with a therapy consisting of three doses per day of insulin lispro in the context of an established OAD therapy ( Bretzel et al., 2008, EC Ib ). In this case, HbA1c was lowered comparably with both therapies, but the once daily administration of insulin glargine was associated with fewer hypoglycaemia episodes (5.2 vs. 24 events per patient per year) and better patient satisfaction than the therapy with three daily doses of insulin lispro ( Bretzel et al., 2008, EC Ib ).
Side eff ects of insulin therapy
Hypoglycaemia: These occur considerably more frequently with insulin therapy than with treatments using oral antidiabetics. For example, the incidence of severe hypoglycaemia in the UKPD study was 2. , it should also be borne in mind that lowering HbA1c to 6.5 % as opposed to a target value of 7.0 % can be benefi cial to the patient, but should only be attempted if ▶ hypoglycaemia (particularly severe hypoglycaemia) are largely prevented, ▶ the therapeutic eff ect is not accompanied by excessive weight gain, ▶ multiple combinations of oral antidiabetics (i. e. usually more than two) on which little research has been done, and particularly continuation of such multiple combinations when supplementing with insulin are avoided. (see also section 4 (appendix 1)) The HbA1c value should be determined every 3 months. If the therapeutic objective for the HbA1c is not achieved, the therapy is intensifi ed. Once the HbA1c value is stabilised in the target range, another option consists in attempting a treatment pause (e. g. for insulin), whereby patient can be treated experimentally (and as a rule temporarily) at the earlier therapy stage.
Education, nutrition and exercise therapy, metformin &
Patients who have recently been diagnosed with diabetes mellitus type 2 should attend a formal diabetes education programme. Among the value of information provided at such sessions, they will learn the principles of nutritional and exercise therapy. The eff ectiveness of non-pharmacological therapy is refl ected in the fact that it is capable of lowering the HbA1c by about 2 % (UKPDS 34, 1998, EC Ib) (recommendation grade A). A metformin therapy should be started as soon as possible ( Nathan et al., 2006 , EC IV) (recommendation grade A), provided no contraindications exist (see 1.1.1.1.8). For information about metformin titration, see page 43. If a contraindication or intolerance for metformin does exist, therapy is recommended with a substance that is approved for monotherapy (acarbose, PPAR-γ ligands, repaglinide, sulphonylurea (alphabetical list)), if the HbA1c is still > 6.5 % after 3 -6 months of non-pharmacological treatment. Selection of the antihyperglycaemic substance should be made with consideration for diff erential therapeutic considerations and the pertinent spectrum of side eff ects. If the HbA1c value is 6.5 % and < 7.5 % after 3 -6 months, an OAD / exenatide combination therapy is recommended (see below, 2.). If the HbA1c value is 7.5 % after 3 -6 months, an insulin / OAD (particularly metformin) combination therapy is recommended (see below 3.), since a combination therapy listed under 2. (generally causing a further reduction of HbA1c of < 1 % , ) is unlikely to achieve the HbA1c target of < 6.5 % in patients who have received prior non-pharmacological treatment and metformin.
OAD combination therapy, OAD / exenatide combination therapy &
At this level of therapy, the combinations shown in the fl owchart can be used. They are listed in alphabetical order. There is no scientifi cally based order of preference. The choice of combination partners must be made on a case by case basis in accordance with the patient ' s current metabolic situation and taking into account the advantages and disadvantages as well as side eff ects / contraindications of the respective substance. Combination therapies with two OADs or OADs with exenatide are not advisable unless the HbA1c target appears to be achievable in view of the degree by which the selected substances can be expected to lower HbA1c. With regard to the combination therapy metformin / glibenclamide, according to the published data currently available, it cannot be guaranteed that this combination will not increase cardiovascular risk. Therefore, this combination should only be administered if alternatives of equivalent effi cacy cannot be used and after the patient has been informed in detail about the possible risk and alternative therapies. Due to the lack of pertinent data, it is not known whether other SU or SUA / metformin combination therapies are associated with a similar possibility of increased risk. In this situation, the authors do not believe that it is necessary to change the medications for all diabetics who are being treated with these combinations, but they suggest a more rigorous indication system is called for, particularly for new patients and patients with coronary heart disease. A combination of three OADs should not be used except in special circumstances (e. g. need to avoid insulin therapy for reasons related to the patient ' s profession). If the HbA1c therapeutic target of < 6.5 % is not achieved after 3 -6 months, treatment is intensifi ed with a combination therapy consisting of insulin and OAD (see below, 3.).
Combination therapy OAD (particularly metformin) plus insulin &
In this phase of the disease, the patient ' s metabolism is characterised primarily by fasting glucose values that are above the target value of 100 mg / dl, since endogenous glucose production is no longer adequately suppressed by endogenous insulin. Thus, the objective of insulin therapy is to compensate for this deficiency. For this, basal insulins are recommended. They are injected at bedtime in the evening and thus block endogenous glucose production (also called basal insulin supported o ral t herapy, BOT). The dose of these basal insulins is titrated so as to achieve a fasting blood glucose level of 100 mg / dl while avoiding nocturnal hypoglycaemia (Yki-J ä rvinen, 1999, EC Ib) (recommendation grade A). If plasma glucose levels during the day remain near to normal with this therapy, there is currently no need for escalating insulin therapy using also injections during daytime. In the (much rarer) event that with this regimen the fasting blood sugar level is in the normal range but the preprandial blood sugar levels during the day are not in the target range, prandial insulin therapy should be implemented (also called s upplementary i nsulin t herapy, SIT).
In the absence of contraindications, the respective combination therapy with metformin is recommended (Ponssen et 
Metformin titration
Start with 1 × 500 mg with the evening meal (0-0-1). If tolerated, increase after 1 week to 2 × 500 mg with breakfast and evening meal (1-0-1). If tolerated, increase after 1 week to 2 × 1 g with breakfast and evening meal (1-0-1). If the patient develops an intolerance in response to the dosage increase, the dose should be reduced to the level at which it is tolerated. If possible, a further attempt should be made to increase the dosage later Abbreviations HbA1c, glycosylated haeoglobin; OAD, oral antidiabetics; SU, sulphonylureas; SUA, sulphonylurea analogues (repaglinide, nateglinide); α -GI, α -glucidase inhibitor; glitazone, PPAR-γ ligand (rosiglitazone, pioglitazone); MDI, multiple daily injection of basal / bolus insulins; CSII, continuous subcutaneous insulin infusion, (insulin pump therapy); Premixed bid, injection of premixed insulin preparations twice daily; partic., particularly; a, after. 
References
Introduction
The eff ect of near normoglycaemic metabolic control on the reduction of microvascular complications (e. g. nephropathy, retinopathy) in patients with type 2 diabetes is well documented [286, 287] . On the other hand, the number of studies on the eff ect of near normoglycaemic metabolic control on macrovascular complications (e. g. myocardial infarction, stroke) is comparatively less extensive and is essentially based on the results of the UKPDS, which after 10 years revealed a clear downward trend in myocardial infarctions, which however did not quite reach the level of signifi cance (p = 0.052 [286] ). On the other hand a non-significant rise in strokes, by 11 % in relative terms, was observed in the intensifi ed arm of blood glucose reduction. The 10-year followup review of the results of the UKPDS are will be presented at this year ' s EASD Congress.
In this context, the results of two large studies that examined the eff ect of close to normal glucose metabolism control on macrovascular (ACCORD) and macro-and microvascular (ADVANCE) complications were presented at this year ' s Congress of the American Diabetes Association (6.-10.6.). Both studies were published in the New England Journal of Medicine to coincide with the presentation [288, 289] .
Design and results of the ACCORD study
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study examined the eff ect of intensifying control of blood glucose, blood pressure and lipids on macrovascular complications compared with standard therapy. The results of the blood pressure and lipid therapy are expected to be published in 2010. The increased rate of mortality in the group receiving intensifi ed antihyperglycaemic therapy caused this therapy arm of the study to be discontinued prematurely in February 2008, after 3.5 years, and the results thereof were published in June 2008 [288] . A total of 10,251 patients were recruited at 77 centres in the USA and Canada. In the group receiving intensifi ed treatment the HbA1c target value was < 6.0 % , in the group receiving standard therapy the target HbA1c value was in a range from 7.0 -7.9 % . All approved substances with antihyperglycaemic eff ects (OADs, exenatde, insulin) could be used to achieve these targets, even combination therapies were unrestricted, in terms of either the number or type of substances used. Defi nition of the primary endpoint: -Non-fatal myocardial infarction, -Non-fatal stroke, -Death from cardiovascular causes. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. group was 7.5 % . In order to achieve these targets, the following procedure was established for the intensifi ed treatment group: ▶ Intensifi cation of non-pharmacological therapy options ▶ Escalation of therapy by attending physision on the basis of HbA1c and fasting blood sugar levels, taking into account the following recommendations: ▶ Escalation of the gliclazid-MR dose ▶ Supplementing with other OADs ▶ Supplementing with a long-acting insulin ▶ Intensifi ed insulin therapy (multiple insulin injection therapy) 
Summary
The primary endpoint was lowered by 10 % in relative terms (p = 0.01). The main reason for this eff ect was a signifi cant reduction in nephropathy, by 21 % in relative terms (p = 0.006).
Overall mortality was lowered non-signifi cantly, by 7 % in relative terms (p = 0.28). Macrovascular events were lowered nonsignifi cantly, by 6 % in relative terms (p = 0.32).
The number of severe hypoglycaemia in the group receiving intensifi ed therapy was 0.7 % / year, higher than in the group receiving standard therapy (0.4 % / year). The group receiving intensifi ed therapy experienced no weight gain, the group receiving standard therapy experienced an average weight loss of 1.0 kg. Table 3 shows a comparison summary of the essential parameters of the two studies.
Comparative consideration of ACCORD and ADVANCE
Note on patient characteristics
The patient characteristics show that the patient cohorts recruited in both studies displayed similarities in terms of age, duration of diabetes and percentage with pre-existing macrovascular diseases. The HbA1c target values achieved were comparable.
Note on intensifying antihyperglycaemic therapy
The ways in which antihyperglycaemic therapy was intensifi ed present marked diff erences: Whereas a polypharmacotherapeutic approach was adopted in the ACCORD study (by the end of the study ~ 70 % of patients not treated with insulin and ~ 60 % of those treated with insulin were receiving combination therapies with 3, 4, or 5 OADs), the ADVANCE study used an algorithm to determine a supplementary regimen of insulin with lasting eff ects if the HbA1c target value of < 6.5 % was not achieved using OADs alone. If a further escalation in therapy became necessary This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
in order to achieve the HbA1c target value, intensifi ed insulin therapy using basal and prandial insulin was recommended.
Note on results regarding eff ect on mortality
The conspicuous eff ect of increased mortality in the group receiving intensifi ed treatment in the ACCORD study was not observed in the ADVANCE study, which recorded comparable results for HbA1c target value achievement.
4.4.4 Note on side eff ects of intensifi ed therapy
Hypoglycaemia
The group receiving intensifi ed treatment in the ACCORD study experienced severe hypoglycaemia at a rate 3.1 times greater than the standard treatment group, overall 16.2 % of the patients in this group suff ered a severe hypoglycaemia episode In the ADVANCE study, the rate of severe hypogylycaemia was 0.7 % / year, slightly higher than in the standard therapy group (0.4 % / year), but lower than in the standard therapy group of the ACCORD study (1.0 % / year) -with a diff erence of 1.0 % (6.5 % (ADVANCE (int.) vs. 7.5 % (ACCORD (std.))) in the average HbA1c value.
Weight gain
The average weight gain of patients in the ACCORD study was 3.5 kg, 27.8 % of the patients experienced a weight gain of > 10 kg. The patients in the group receiving intensifi ed treatment in the ADVANCE study experienced no weight gain ( + / -0.0 kg).
Conclusions
The results of the ADVANCE study show that intensifi ed antihyperglycaemiec therapy that aims to achieve an HbA1c target value of < 6.5 % while avoiding side eff ects (hypoglycaemia, weight gain) is associated with signifi cantly reduced recurrence or progression of nephropathy, by 21 % in relative terms (NNT 91 for 5 years). Macrovascular endpoints were not signifi cantly reduced by the end of the 5-year study.
The results of the ACCORD study show that lowering the HbA1c to below 6.5 % -under the conditions of this study -can increase mortality due to myocardial infarction. The diff ering results from these two studies indicate that the way in which antihyperglycaemic therapy is intensifi ed is of crucial importance to the success of the therapy. The conclusion derived from the studies for application in practical therapy is that lowering HbA1c to 6.5 % as compared with a target value of 7.0 % can be benefi cial for the patient, but should only be aimed for provided that ▶ hypoglycaemia (particularly severe hypoglycaemia) can be largely prevented, ▶ the therapeutic eff ect is not associated with signifi cant weight gain, ▶ inadequately documented combinations of multiple oral diabetics (i. e., generally more than two) are avoided, and particularly that such multiple combinations are discontinued if treatment with insulin is begun. The polypharmacotherapeutic procedure adopted in the ACCORD study (with the side eff ects described above) is not recom-mended in the territory for which the DDG guideline is authoritative. Instead, the guideline recommends a procedure with preferential use of a non-hypoglycaemia inducing substance (metformin) as the medium of fi rst choice [292] and also the use of insulin, if the HbA1c target value is no longer reached with a combination therapy consisting of no more than two OADs. In the light of the results of the ACCORD and ADVANCE studies, the DDG guideline on " Antihyperglycaemic treatment of type 2 diabetes " has been supplemented with a statement to the eff ect that avoidance of side eff ects (hypoglycaemia, signifi cant weight gain) is a primary objective, even at the cost of allowing the HbA1c target value to remain at 7.0, if a target value of < 6.5 % can only be achieved with the side eff ects described above. The guidelines commission will respond promptly to the publications on this subject that are expected soon (e. g. further analyses of the ACCORD study, VADT, results of the 10-year follow-up review of the UKPDS (presentation on 10.9.08 on the EASD, BARI-2D etc.), and will adapt its recommendations for treating type 2 diabetes to the latest status of published evidence as necessary, in keeping with the guidelines of the the EASD and IDF. DDG President DDG Managing Board DDG Pharmacotherapy Committee DDG Guidelines Commission (Antihyperglycaemic treatment of type 2 diabetes mellitus)
